Medicare Unlocks Affordable GLP-1s: $50 Monthly for Weight Loss, But Not For Everyone

A game-changing shift just hit millions of older Americans: Starting July 1, 2026, Medicare is now covering certain popular GLP-1 weight loss drugs for a fixed $50 monthly co-pay through a temporary 'Medicare GLP-1 Bridge' program. This move shatters a longstanding prohibition on Medicare paying for medications solely for weight loss, making expensive treatments like Wegovy, Zepbound, and Foundayo suddenly affordable for eligible beneficiaries across the country. This isn't just about weight loss; it's a massive policy pivot by the Centers for Medicare & Medicaid Services (CMS) that impacts the skyrocketing costs of these drugs and the health of nearly 3.8 million potentially eligible seniors. While drugs like Ozempic and Mounjaro are covered for diabetes, this new Bridge program specifically targets obesity, requiring a doctor's 'Prior Authorization' and strict eligibility based on Body Mass Index (BMI) and other health conditions. Pharmaceutical giants like Novo Nordisk and Eli Lilly, makers of these blockbuster medications, will see a significant expansion in patient access. However, there's a catch: the Medicare GLP-1 Bridge is a temporary pilot, set to expire on December 31, 2027, with the replacement 'BALANCE Model' indefinitely delayed. This leaves millions of beneficiaries in limbo about continued coverage after 2027, potentially facing a return to high out-of-pocket costs. Healthcare providers and pharmacies are bracing for increased demand and new administrative processes, highlighting the need for a long-term solution to ensure sustained access to these transformative treatments.